Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Recommendation of "Buy" by Analysts

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has received an average rating of "Buy" from the seven ratings firms that are presently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $19.80.

CATX has been the topic of several recent analyst reports. Bank of America initiated coverage on Perspective Therapeutics in a research note on Thursday, July 25th. They issued a "buy" rating and a $24.00 price target on the stock. Lifesci Capital reiterated an "outperform" rating on shares of Perspective Therapeutics in a research note on Monday, May 6th. Oppenheimer decreased their price target on Perspective Therapeutics from $19.00 to $17.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 13th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Perspective Therapeutics in a research note on Tuesday, June 25th. Finally, Royal Bank of Canada decreased their price target on Perspective Therapeutics from $29.00 to $27.00 and set an "outperform" rating on the stock in a research note on Friday, August 16th.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock traded down $0.36 during mid-day trading on Thursday, reaching $14.96. 497,768 shares of the company were exchanged, compared to its average volume of 602,729. The firm's fifty day simple moving average is $12.08. Perspective Therapeutics has a 12 month low of $2.05 and a 12 month high of $19.05. The company has a debt-to-equity ratio of 0.01, a current ratio of 12.98 and a quick ratio of 12.98.

Insider Buying and Selling

In other news, CFO Jonathan Robert Hunt acquired 2,500 shares of Perspective Therapeutics stock in a transaction that occurred on Friday, May 31st. The shares were acquired at an average price of $14.00 per share, for a total transaction of $35,000.00. Following the transaction, the chief financial officer now directly owns 34,171 shares of the company's stock, valued at approximately $478,394. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Jonathan Robert Hunt bought 2,500 shares of the business's stock in a transaction on Friday, May 31st. The shares were purchased at an average cost of $14.00 per share, with a total value of $35,000.00. Following the acquisition, the chief financial officer now owns 34,171 shares of the company's stock, valued at $478,394. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Robert F. Williamson III bought 5,500 shares of the business's stock in a transaction on Friday, May 31st. The shares were bought at an average cost of $13.80 per share, for a total transaction of $75,900.00. Following the completion of the acquisition, the director now directly owns 42,379 shares in the company, valued at approximately $584,830.20. The disclosure for this purchase can be found here. Insiders have bought 30,814 shares of company stock worth $385,487 in the last 90 days. Insiders own 3.52% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company acquired a new position in Perspective Therapeutics during the 2nd quarter worth about $188,000. Point72 DIFC Ltd acquired a new position in Perspective Therapeutics during the 2nd quarter worth about $118,000. Ally Bridge Group NY LLC acquired a new position in Perspective Therapeutics during the 2nd quarter worth about $3,951,000. HighVista Strategies LLC acquired a new position in Perspective Therapeutics during the 2nd quarter worth about $1,132,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Perspective Therapeutics by 94.2% in the 2nd quarter. Renaissance Technologies LLC now owns 61,660 shares of the company's stock valued at $615,000 after purchasing an additional 29,914 shares during the period. 54.66% of the stock is owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.